Elevai Labs Reports Promising Early Results in Androgenic Alopecia Study
In a recent press release, Elevai Labs shared “encouraging data results” from an ongoing study conducted by its subsidiary, Elevai Skincare Inc. While full details are not yet available, the release highlighted that the study focuses on treating androgenic alopecia using Elevai’s exosome-based therapies.
Study Overview
Participants in the study underwent both in-clinic and at-home treatments:
At-Home Treatment: Participants used Elevai enfinity™, a topical exosome-infused treatment, on balding areas of the scalp as part of their home care routine.
In-Clinic Treatment: Patients received Elevai empower™, a serum formulated with exosomes specifically for professional use. Scalp needling was performed prior to applying the serum to enhance absorption.
Preliminary Results
After 12 months, imaging revealed several positive trends:
- Reduction in crown inflammation
- Fewer miniaturized hairs
- A decrease in hairs remaining in the telogen (non-growing) phase
Next Steps and Future Research
The results from this study will contribute to the development of Elevai’s new hair and scalp care line, the Elevai S-Series Root Renewal System™. This product line incorporates Elevai’s proprietary PREx™ technology alongside Yuva Bioscience’s Y100 mitochondrial technology. The system will feature a shampoo, conditioner, and serum designed to promote hair health and growth.
Next Steps and Future Research
While these early findings are promising, more comprehensive data is needed to draw definitive conclusions about the effectiveness of these treatments. As we await the full release of study results, it’s worth noting the ongoing collaboration between Elevai Labs and Yuva Biosciences. Yuva’s Y100 compound targets mitochondrial dysfunction, a factor that plays a critical role in aging-related issues in both hair and skin, further bolstering the potential of this partnership to develop innovative therapies.
SHOP FOR HAIR LOSS TREATMENTS
